Literature DB >> 34470554

Neuroprotective effect and potential of cellular prion protein and its cleavage products for treatment of neurodegenerative disorders part II: strategies for therapeutics development.

Emily Dexter1, Qingzhong Kong1,2.   

Abstract

Introduction: The cellular prion protein (PrPC), some of its derivatives (especially PrP N-terminal N1 peptide and shed PrP), and PrPC-containing exosomes have strong neuroprotective activities, which have been reviewed in the companion article (Part I) and are briefly summarized here.Areas covered: We propose that elevating the extracellular levels of a protective PrP form using gene therapy and other approaches is a very promising novel avenue for prophylactic and therapeutic treatments against prion disease, Alzheimer's disease, and several other neurodegenerative diseases. We will dissect the pros and cons of various potential PrP-based treatment options and propose a few strategies that are more likely to succeed. The cited references were obtained from extensive PubMed searches of recent literature, including peer-reviewed original articles and review articles.Expert opinion: Concurrent knockdown of celllular PrP expression and elevation of the extracellular levels of a neuroprotective PrP N-terminal peptide via optimized gene therapy vectors is a highly promising broad-spectrum prophylactic and therapeutic strategy against several neurodegenerative diseases, including prion diseases, Alzheimer's disease and Parkinson's disease.

Entities:  

Keywords:  ADAM; Alzheimer’s disease; Aβ and other toxic oligomers; N1 peptide; alpha-cleavage; neurodegenerative diseases; neuroprotection; prion protein; shedding; therapeutics

Mesh:

Substances:

Year:  2021        PMID: 34470554      PMCID: PMC8453096          DOI: 10.1080/14737175.2021.1965882

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.287


  120 in total

Review 1.  Isolation of extracellular vesicles with combined enrichment methods.

Authors:  Janine Stam; Sabine Bartel; Rainer Bischoff; Justina C Wolters
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2021-02-27       Impact factor: 3.205

Review 2.  The metalloproteinase ADAM10: A useful therapeutic target?

Authors:  Sebastian Wetzel; Lisa Seipold; Paul Saftig
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2017-06-15       Impact factor: 4.739

Review 3.  Taking advantage of physiological proteolytic processing of the prion protein for a therapeutic perspective in prion and Alzheimer diseases.

Authors:  Maxime Béland; Xavier Roucou
Journal:  Prion       Date:  2014 Jan-Feb       Impact factor: 3.931

4.  Phorbol ester-regulated cleavage of normal prion protein in HEK293 human cells and murine neurons.

Authors:  B Vincent; E Paitel; Y Frobert; S Lehmann; J Grassi; F Checler
Journal:  J Biol Chem       Date:  2000-11-10       Impact factor: 5.157

5.  Soluble prion protein inhibits amyloid-β (Aβ) fibrillization and toxicity.

Authors:  Krzysztof Nieznanski; Jin-Kyu Choi; Shugui Chen; Krystyna Surewicz; Witold K Surewicz
Journal:  J Biol Chem       Date:  2012-08-22       Impact factor: 5.157

6.  A new paradigm for enzymatic control of α-cleavage and β-cleavage of the prion protein.

Authors:  Alex J McDonald; Jessie P Dibble; Eric G B Evans; Glenn L Millhauser
Journal:  J Biol Chem       Date:  2013-11-18       Impact factor: 5.157

Review 7.  α-Cleavage of cellular prion protein.

Authors:  Jingjing Liang; Qingzhong Kong
Journal:  Prion       Date:  2012-10-10       Impact factor: 3.931

8.  Lack of a-disintegrin-and-metalloproteinase ADAM10 leads to intracellular accumulation and loss of shedding of the cellular prion protein in vivo.

Authors:  Hermann C Altmeppen; Johannes Prox; Berta Puig; Mark A Kluth; Christian Bernreuther; Dana Thurm; Ellen Jorissen; Bettina Petrowitz; Udo Bartsch; Bart De Strooper; Paul Saftig; Markus Glatzel
Journal:  Mol Neurodegener       Date:  2011-05-27       Impact factor: 14.195

9.  Neuroprotective effect and potential of cellular prion protein and its cleavage products for treatment of neurodegenerative disorders part II: strategies for therapeutics development.

Authors:  Emily Dexter; Qingzhong Kong
Journal:  Expert Rev Neurother       Date:  2021-09-02       Impact factor: 4.287

Review 10.  Regulation of A disintegrin and metalloproteinase (ADAM) family sheddases ADAM10 and ADAM17: The emerging role of tetraspanins and rhomboids.

Authors:  Alexandra L Matthews; Peter J Noy; Jasmeet S Reyat; Michael G Tomlinson
Journal:  Platelets       Date:  2016-06-02       Impact factor: 3.862

View more
  2 in total

Review 1.  Anchorless risk or released benefit? An updated view on the ADAM10-mediated shedding of the prion protein.

Authors:  Behnam Mohammadi; Feizhi Song; Andreu Matamoros-Angles; Mohsin Shafiq; Markus Damme; Berta Puig; Markus Glatzel; Hermann Clemens Altmeppen
Journal:  Cell Tissue Res       Date:  2022-01-27       Impact factor: 5.249

2.  Neuroprotective effect and potential of cellular prion protein and its cleavage products for treatment of neurodegenerative disorders part II: strategies for therapeutics development.

Authors:  Emily Dexter; Qingzhong Kong
Journal:  Expert Rev Neurother       Date:  2021-09-02       Impact factor: 4.287

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.